Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor

Many studies have illustrated that two types of mutation – deletions in exon 19 and a point mutation in exon 21 (L858R) – have been reported to comprise up to 90% of all activating epidermal growth factor receptor (EGFR) mutations. A point mutation at exon 19 is a rare mutation, and to date there ha...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Thorac Cancer
Egile Nagusiak: Zheng, Hua, Wang, Qunhui, Shi, Heling, Zhang, Hongmei, Hu, Fanbin, Li, Baolan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BlackWell Publishing Ltd 2014
Gaiak:
Case Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704356/
https://ncbi.nlm.nih.gov/pubmed/26767025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12096
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak